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Abstract Diabetes mellitus (DM) is a metabolic disease
affecting the regulation of insulin and glucose causing a
disruption in the normal control of counterregulatory
hormones and macronutrients, resulting in blood glucose
accumulation. Metabolic deregulation leads to the produc-
tion of noxious substances that have a particular propensity
for damaging vascular and nervous structures. Physiologi-
cal changes observed with aging are correlated with a
concomitant increase in DM and its associated complica-
tions. Long-term complications, including peripheral and
central neuropathies, micro- and macrovascular damage,
retinopathy, and nephropathy are the major causes of
mortality in diabetics [cardiovascular disease (CVD) being
the primary complication causing death in this population].
All-cause mortality is three to four times greater in the DM
population; hence, management of DM is of timely
importance, particularly with a projected prevalence in-
crease of 134% within the next 25 years among individuals
over the age of 65 years. Exercise modalities, including
endurance and resistance training, were employed to
improve glycemic/metabolic control and to ameliorate the
progression of DM-related complications. Several risk
factors, including glucose levels, blood pressure, lipid/
cholesterol profile, and BMI, are reportedly improved with
these modes of exercise. However, not all studies demon-
strate an improvement in risk factors, but consistently note
improvement in complications and a reduction of DM
incidence. There is convincing evidence that exercise, with
or without specific improvements to traditional DM-related
risk factors, is an effective therapy for the management of
DM.
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Introduction
Diabetes mellitus (DM) is a metabolic pathology charac-
terized by systemic circulatory glucose accrual, accompa-
nied by diminishing cellular glucose uptake and
metabolism. Diabetic metabolism is also evidenced by
elevated counterregulatory hormones, which alters lipid
metabolism and increases protein catabolism [34]. Sequelae
of diabetes may include microvascular complications
involving retinopathy, nephropathy, and neuropathy (distal
symmetric polyneuropathy and autonomic neuropathy), and
macrovascular complications culminating in coronary ar-
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tery disease. All-cause mortality is three to four times
greater in patients with DM, with CVD accounting for the
majority of deaths [93]. The senior population demonstrates
a particular susceptibility to DM with a prevalence rate of
more than half of all DM cases. With one in five seniors
suffering from DM and the deleterious impairments
attributed to its pathophysiology, a clear need for treatment
and prevention is evident in this growing population. In
2000, the World Health Organization [106] estimated 177
million people suffered from DM. This was a 31% increase
over 5 years, up from 135 million in 1995, and an
astonishing 490% increase over the 1985 estimate of 30
million. The WHO projects 350 million people will suffer
from diabetes by 2030, and that DM may account for ∼9%
of the total global causes of death [107].
DM is one of the most extensively studied pathologies,
spanning centuries. Moreover, the observation that DM was
a condition that indicated elevated glucose in urine led to
the recommendation, over 2000 years ago, that exercise be
used as a treatment [96]. The present review is not
comprehensive, but will attempt to delineate some of the
current perspectives on DM and will focus on the numerous
physiological effects of DM and the potential for aerobic
and resistance exercise to ameliorate and prevent the
disease and its various accompanying pestilence within
the senior demographic.
Diabetes and aging
Age-associated decline of personal vitality is generally
accepted as a congenital axiom. Increased susceptibility to
disease with increasing age is likewise axiomatic. Hence,
age-associated physical discompositions, such as DM, heart
disease, cancer, and stroke, ranging in degree from
asymptomatic to death, may be perceived as immutable
and intrinsically human. Comorbidity increases with age
(from ∼35% of patients over 65 to ∼70% of patients over
80), as does the cost of treating patients who present with
comorbidity [35]. In addition, comorbidity leads to an
underreporting of deaths attributed to DM, as fatal events
attributed to heart disease and stroke, for example, may not
be ascribed to DM. Not surprisingly, decreased life
expectancy of ∼4 years among individuals diagnosed with
DM aged 65–74 was reported [40]. The fact that all-cause
mortality is three to four times greater in the DM population
attests to its principal role in the lives of seniors. Not only
does this amount to massive health care expenditures, but
also represents a significant individual financial burden
(direct and indirect costs totaling ∼132 billion US dollars or
∼111 billion euros in 2002 in the United States [46]). It is
predicted that by the year 2030 the number of individuals
over 65 who suffer from DM will increase by 134%. The
progressive nature of DM suggests that the more senior
elderly demographic will suffer; between the years 2000
and 2050 the largest increase in DM prevalence is predicted
to be among the elderly with the more represented senior
demographic being above 75 years (271% increase in
women and 437% increase in men) [12]. The prevalence of
DM in adults older than 60 years is estimated at ∼25% [41].
Imperative to a full account of the impact of accumulat-
ing comorbid infirmities, in addition to recognizing the
direct metabolic stress of DM, is accounting for the
potential for a given intervention to affect the progress
and manifestation of the disease. For example, aging is
associated with a mortality-related decline in muscle
strength [80], a decline in muscle mass [17], decreased
oxygen consumption capacity (VO2max), and a concomitant
increase in fat mass [86], along with increased disability
[10]. DM is coincidently related to increased adiposity [5],
decreased muscle mass [94], and an elevated waist
circumference (associated with both DM [79] and metabol-
ic syndrome [59]). Curiously, DM is also associated with
altered mitochondrial function relative to normal individu-
als, suggesting diminished VO2max, and exercise capacity
associated with DM may be related to a unique mitochon-
drial phenotype [68]. Therefore, it is logical to propose that
therapies aimed at reducing these age-related anthropomor-
phic and physiological changes (for example, via exercise
intervention) may provide a stimulus, which is able to
reverse or prevent age- and disuse-associated physiological
changes and, thereby, reduce DM and its comorbidities.
However, aging may also be inherently associated with
progressive physiological changes, including those leading
to an increased incidence of DM, which may remain
unaffected by exercise (reviewed by Degens and Alway
[26] and Karakelides and Sreekumaran Nair [58]). In light
of the predictive statistics for DM and the economic and
personal cost of the disease, it seems an intuitive respon-
sibility to seek out etiologies and treatment for this
sweeping threat.
DM symptoms
Primarily, DM is a metabolic disorder that manifests
through its varied effects on levels of circulatory and
intracellular energy substrates with the inherent character-
istic of high plasma glucose levels. Individuals are
considered normal with a fasting plasma glucose (FPG) of
<100 mg/dl (5.6 mmol/l). A positive DM diagnosis is
contingent upon obtaining a FPG level ≥126 mg/dl
(7.0 mmol/l) [4]. This measurement must be repeated on a
subsequent day to confirm the diagnosis. A casual measure
(regardless of time of day or time between meals) of plasma
glucose ≥200 mg/dl (11.1 mmol/l) is also suspect for DM
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when combined with additional symptoms, which may
include unexplained weight loss, increased appetite, fre-
quent urination (polyuria), excessive thirst (polydipsia),
blurred vision, nausea, mental confusion, and fatigue. A
third test frequently employed to determine hyperglycemia
is an oral glucose tolerance test (OGTT). An OGTT is the
oral administration of ∼75 g of water-solubilized glucose:
2 h postingestion, a blood glucose ≥200 mg/dl (11.1 mmol/l)
is provisionally indicative of DM. The essence of these
tests is to confirm consistent hyperglycemia resulting from
the inability to dispose of glucose due to insulin insuffi-
ciency and/or insulin resistance and/or decreased receptor
sensitivity. Therefore, any one of these tests needs to be
repeated to confirm the glucose profile inherent to DM.
Because hyperglycemia is a hallmark symptom of DM it
may also be a monolithic miscreant singularly responsible
for the multifarious maladies observed with disease
progression. Indeed, insulin resistance and numerous
micro- and macrovascular abnormalities can be correlated
with hyperglycemia, but hyperlipidemia was also proposed
as a contributor to DM-associated cellular dysfunction.
Moreover, the clinical and biochemical summary list of
symptoms and characteristics does not conclusively eluci-
date the inciting incident inevitably leading to the chronic
disease. Prudence dictates and current knowledge limits us
to an examination of pathophysiology and potential
mechanisms of cellular injury proposed in the published
literature. Ideally, examining DM symptoms and patho-
physiology could expose the potential for exercise and
physical activity as a therapy and method of prevention in
the lives of seniors.
Etiology
Central to glucose metabolism is (1) a proportional
pancreatic release of insulin that (2) effects insulin receptor
agonization leading to (3) intracellular glucose transporter-4
(GLUT4) translocation resulting in (4) subsequent cellular
glucose uptake. DM may be represented by impairment at
all four levels of glucose metabolism. DM is generally
characterized by one of two types (gestational diabetes will
not be discussed and is, in all likelihood, irrelevant in this
review). Primarily, DM type 1 (DM1) is the complete
absence of pancreatic insulin secretion due to beta cell
autoimmune destruction resulting in insufficient cellular
glucose uptake. Disease progression proceeds through the
inability to regulate and dispose of excess glucose and
glucose by-products and via elevated catabolism and lipid
metabolism. DM type 2 (DM2) typically includes relatively
insufficient insulin secretion with compounded cellular
insulin resistance. DM2 is represented in 90–95% of all
cases of DM [4]. A common perception is that DM1
originates at the level of pancreatic function whereas DM2
originates at the level of insulin receptor function. There-
fore, the former is a disease of prima organum (first organ)
whereas the later is finalis portus (final port). However, this
distinction may not be borne out through closer pathophys-
iological examination of each disease, i.e., a great similarity
exists between the two disease states. Functionally, the
long-term and acute complications of DM (retinopathy,
nephropathy, neuropathy, CVD, ketoacidosis, hyperglyce-
mic hyperosmolar nonketotic syndrome, and hypoglyce-
mia) can be sequelae of either phenotype.
Beta cell dysfunction vs insulin resistance is often
perceived as the pillar supporting the division between
DM1 and DM2. It is generally accepted that DM1 is the
result of autoimmune destruction of insulin-secreting
pancreatic beta cells. Hence, a singular crime, albeit with
multiple suspects, leads to DM1. It was suggested that beta
cell destruction and dysfunction might be central to
initiating the progression of DM2 (reviewed by Khan and
Chakrabarti [62] and Rhodes [89]). An estimated 41 to 63%
lower beta cell volume was observed in lean and obese
individuals with DM2, respectively [15], with a selective
decrease of beta cell mass and alpha cell increase, which
correlated with BMI [108].
It is not clear whether beta cell destruction is an
initiating factor leading to hyperglycemia and dyslipidemia
in DM2 or an increasing variable responding to hypergly-
cemia, dyslipidemia, and insulin resistance. For instance,
intracellular palmitate was shown to directly induce insulin
resistance/impaired glucose uptake by downregulating
GLUT4 via protein kinase C (PKC) activation [56],
indicating a possible mechanism for hyperglycemia and
hyperinsulinemia, independent of beta cell function and
insulin quality. Nonetheless, both hyperglycemia [71]
and elevated levels of free fatty acids [45] were shown to
induce beta cell destruction, although through different
mechanisms. Moreover, the mechanism of free fatty acid-
induced beta cell destruction appears to be different than
cytokine-induced apoptosis [64], which may indicate a
unique etiology for DM1 autoimmune beta cell destruction
and DM2. Regardless, both DM1 and DM2 similarly
present with insulin quality and secretion abnormalities
[3], hyperglycemia, hyperlipidemia, and hyperglucagone-
mia [9, 19], possibly due to beta cell destruction and/or
alpha and beta cell miscommunication [67].
Genetics of DM
Genetic factors exist for the development of both DM1 and
DM2, although DM2 demonstrates a greater inheritability
than DM1. The susceptibility of pancreatic beta cells to
cytokine-, fatty acid-, glucose-, or lipoprotein-induced
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destruction may be partly genetically influenced, as the
concordance (probandwise) for the DM1 phenotype in
monozygotic twins was reported to be 42.9% and only
3.8% in dizygotic twins [52]. Twins (median age of
55 years) with only one member originally diagnosed with
DM2 showed a concordance (pairwise) rate of 76% within
15 years of initial assessment; the additional variable of
impaired glucose tolerance increased the DM2 concordance
rate to 96% [76]. Although susceptibility to the disease
state may be partly inheritable, there exists an undeniable
link between life style and disease progression, as
evidenced by the previously mentioned DM link to body
compositional changes, which are correlated with behav-
ioral activities and disease interventions, such as diet and
exercise. Current abilities to control genetic susceptibility to
DM are lacking. Hence, the ability to control overall
exposure of the internal environment to abnormal levels
of provocative substances, such as glucose and glucose by-
products, is an immediate goal of disease control and
prevention.
Disease progression and complications
The clinical assessment of general exposure to glucose is
accomplished by measuring glycation of the A1(c) form of
hemoglobin (A1C). A nonenzymatically produced keto-
amine or glycation (rather than the enzyme-induced
glycosylation) accumulates on A1C over time. Measuring
A1C will indicate the average exposure of hemoglobin to
glucose over the ∼120-day life span of the red blood cell,
while principally estimating mean blood glucose over the
past 30 days [78]. Clinical tests report A1C as a percentage
of total glycated hemoglobin. The current standard target is
an A1C measurement <7% in non-DM individuals. Al-
though DM generally leads to A1C above 7%, the
measurement per se is not indicative of DM; rather, it is
specific for exposure to high glucose, which is associated
with micro- and macrovascular complications. Ergo, the
American Diabetes Association (ADA) [4] does not
consider an A1C measurement a definitive test for DM.
Glycemic control and the interruption of hyperglycemia-
induced damage pathways have long been recognized as
the most important goals of treatment; inhibition of the
micro- and macrovascular damage pathways is frequently
the target of DM complication intervention studies. How-
ever, not all investigations report significant benefit from
interrupting the activation of these (reviewed by Khan et al.
[63]) and other [28] pathways. Nonetheless, there is
convincing evidence that controlling hyperglycemia and
A1C in DM does confer benefit and reduces micro- and
macrovascular complications (reviewed by Olansky [81]
and Davidson [23]). For example, [90] reported that a high
level of A1C was associated with carotid intima-media
thickness and other CVD risk factors (e.g., lipid profile and
waist circumference). In addition, the joint Canadian–
American Diabetes Control and Complications Trial
(DCCT) (the effect of intensive diabetes therapy, 1995)
and the United Kingdom Prospective Diabetes Study
(UKPDS) have demonstrated that glucose control leads to
significant reduction in micro- and macrovascular (heart
disease) complications (∼30% reduction per 1% reduction
in A1C) [24, 25]. Moreover, the ability to control DM-
associated high blood pressure has also demonstrated
macrovascular/cardiovascular benefit [99].
Several investigations have reported specific biochemi-
cal reactions associated with hyperglycemia that may be at
the heart of vascular complications in DM (reviewed by
Olansky [81]). Conformational changes to red blood cells
via glycation may affect movement through the microvas-
culature and cause damage directly. Possible pestilent
pathways include the polyol pathway [11], the advanced
glycation end-product pathway [36], the diacylglycerol-
stimulated PKC pathway [22], and oxidative stress
(reviewed by Pacher and Szabo [82]). The object of their
biochemical affections appears to be the endothelium:
elevated vascular permeability and basement membrane
thickening related to endothelial dysfunction in DM appear
to be the result of these adversarial actions (reviewed by
Khan and Chakrabarti [62]). As such, latent DM-related
complications, including diabetic autonomic neuropathy
(sympathetic and parasympathetic nerve degeneration) and
especially distal symmetric polyneuropathy (axonal degen-
eration causing numbness and other paresthesias, often
leading to injury and infection and potentially culminating
in amputation), may have a common etiology.
Each DM-related complication has unique and staid
consequences. Some of the more sinister corollaries, even
while manifesting obtrusively, may not always be perceived
as a consequence of DM. For instance, half of all
amputations are performed in individuals with DM [77].
Seniors are at exceptional risk for DM-related amputation
with a threefold increase between the ages of 45–74 and a
sevenfold increase for those over 75 years [88]. It was
projected that up to 65% of diabetic patients will die from
CVD [95]. Moreover, a four- and twofold increased risk for
CVD mortality in diabetic women and men compared with
nondiabetic women and men, respectively, has long been
observed in the scientific community [57]. In younger
individuals, the second most common cause of death is
acute complications (hypoglycemia, hyperglycemic hyper-
osmolar nonketotic syndrome, and ketoacidosis), but this is
shown to decrease with age, accounting for as little as 2%
of mortality between the ages of 40 and 85 years [97].
These data suggest that the vast majority of people
diagnosed with DM (including those receiving treatment)
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will die from the disease. Hence, the massive accumulation
of literature over several centuries has revealed DM to be
exceptionally difficult to manage, in spite of clearly
delineated, partly controllable mechanisms of glucose
regulation. Although DM sequelae are varied and acerbic,
common etiology may provide some insight into potentially
successful interventions.
DM and exercise
Physical activity and physical parameters of fitness
(muscle mass, fat-free mass, strength, and maximum
oxygen consumption) typically decline with age [55],
but exercise demonstrates a clear capacity to improve
these parameters in seniors [49]. Elderly individuals who
show greater fitness levels also demonstrate fewer
negative health problems [91]. A previous review has
revealed an inverse linear dose–response between exer-
cise volume and all-cause mortality [61]. Similarly,
exercise was shown to reduce CVD and all-cause
mortality in people with DM in an inverse dose–response
manner [60]. Several extensive studies have examined
the positive effects of glycemic control on health profiles
in DM, including the Framingham Study [57], DCCT
[25], the UKPDS [74], the Kumamoto Study [92], the
Finnish Diabetes Prevention Study [69], and the Wiscon-
sin Epidemiological Study [66] (the reader is directed to
the original publications and to additional reviews [39]).
The mechanisms of benefit may include (1) augmented
glucose uptake, (2) improved postprandial insulin secre-
tion, (3) lowered hepatic glucose production, (4) in-
creased cellular respiration, (5) elevated resting
metabolism via increased muscle mass, and (6) improved
lipid profile. Studies examining the effect of exercise on
DM in the elderly are remarkably sparse when compared
with the extent of DM research in general. In addition,
more exercise and diabetes researches conducted in older
adults regard prevention rather than treatment. Nonethe-
less, effects of exercise in the elderly generally follow the
same pattern as the effects seen in younger adults,
including improved glycemic control, cellular respira-
tion, strength, and blood pressure, increased muscle
mass, and greater fat loss. In addition, documented
improvements of glycemic control in the aforementioned
studies demonstrate that benefits are conferred upon
representatives of both younger adults and the senior
demographic.
However, not all studies illustrate changes to known
risk factors, despite an observed decrease in CVD
mortality. Therefore, the protective mechanism of
exercise is unclear. Nonetheless, certain variables are
correlated with disease progression and therapeutic
intervention, such as glycemic control, and should be
considered when searching for evidence that exercise
may influence disease status. For example, the UKPDS
and DCCT reported that a reduction of A1C of only 1%
conferred significant reduction in risk of progression and
the development of micro- and macrovascular complica-
tions in the entire cohort of subjects (a previous review of
these studies suggested up to ∼30% reduction per
percentage decrease of A1C [85]). Therefore, in spite of
the modest number of studies specifically examining
exercise-induced prevention and improvements in seniors
with DM, it is important to review those studies that
measured glycemia and other traditionally related varia-
bles and report any changes to DM-related complications
in a multitude of study populations.
Endurance exercise
Several studies revealed a relationship between DM
complications and reduced risk factors derived from
endurance exercise. A recent study in an aged DM
population demonstrated that 1 year of moderate-intensity
aerobic exercise led to a decline in BMI, total cholesterol,
triglycerides, percent body fat, waist circumference, FPG,
A1C, leptin, adiponectin, and C-reactive protein [49]. The
magnitude of change was similar in both the aged group
and a younger cohort and the beneficial changes were
suggested to be derived primarily from weight loss.
Endurance exercise in DM patients was also shown to
improve exercise tolerance, VO2max, A1C (∼1%), in
addition to improving baroreceptor sensitivity (autonomic
function) [70]. Hersey et al. [44] reported increased
capacity of oxygen consumption in elderly men and women
(70–79 years) after 6 months of endurance training at 75–
85% VO2max three times per week.
The subjects in the study by Hersey et al. [43]
demonstrated a lowered plasma insulin response to an
OGTT and decreased body fat compared with control
subjects. In support, Wannamethee et al. [104] reported an
inverse relationship between serum insulin levels and
physical activity in a prospective study involving over
5,000 individuals (age 40–59 years, employing a ∼17-year
follow-up) from 24 towns in England, Scotland, and Wales.
These investigators also demonstrated an inverse relation-
ship between moderate physical activities, such as sports,
once a week or less and more frequent activities (walking
or gardening) with CVD and DM. Rahimi et al. [87] noted
that another CVD marker (C-reactive protein) was inversely
related to exercise capacity in elderly subjects. These
researchers also reported that low exercise capacity
appeared more frequently in older individuals with DM. It
is interesting to note that exercise intolerance was report-
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edly symptomatic of cardiovascular neuropathy in DM
patients [103].
Obesity and CVD mortality
Not all exercise studies showed significant changes in body
composition or glycemic control. Prediction of CVD
mortality in diabetic patients may be better correlated to
fitness. Fitness assessment of over 1,200 men with DM
(mean age 50±10) demonstrated that low cardiorespiratory
fitness and low physical activity were associated with
greater all-cause mortality regardless of normally associated
risk factors, such as body composition, glucose levels, and
baseline CVD [105]. Similarly, in prediabetics, when
baseline values for FPG and BMI were adjusted, Pan et
al. [83] observed that exercise intervention was able to
prevent DM by almost 50%.
Even though a relationship appears between specific risk
factors for both CVD mortality and diabetic complications,
there appears to be a consistent effect of exercise with or
without an observable change to some or all of these risk
factors. A recent study of more than 2,300 individuals with
both DM1 and DM2 examined the influence of cardiore-
spiratory fitness on CVD mortality [20]. This study noted
that higher levels of fat mass and BMI were associated with
lower levels of cardiorespiratory fitness. Even though there
appeared to be an association between CVD mortality and
traditional risk factors (high blood pressure, plasma
glucose, cholesterol, and parental history), at each varying
level of body composition (stratified BMI), cardiorespira-
tory fitness was independently predictive of CVD mortality.
Hence, not all studies demonstrate a requisite exercise-
induced reduction of all risk factors to positively influence
disease progression. Indeed, some trials demonstrate that
the effects of exercise on DM are independent of additional
risk factors.
It seems reasonable that disease control traditionally
attempted to reduce risk factors associated with the
multitude of complications inherent in its progression, such
as by improving lipid profiles in CVD and glycemic control
for micro- and macrovascular complications. As such,
nutritional intervention was intuitively incorporated into
patient management; hence, exercise intervention studies
frequently employed both physical activity and nutritional
recommendations, further confounding the effects of
exercise on DM treatment and prevention. Regardless, even
these studies are equivocal on the beneficial mechanism of
intervention. For example, an exercise intervention with the
addition of diet control revealed reduced mortality inde-
pendent of any changes in glucose tolerance or BMI [32].
In contrast, a 1-year study employing moderate aerobic
exercise (three to four times a week) and nutritional
intervention revealed an improved cholesterol profile
(elevated HDL) and a slight decrease of A1C (Δ=0.5%)
in insulin-resistant individuals [101]. Therefore, the litera-
ture demonstrates that when aerobic exercise is incorporat-
ed into a program designed to treat or prevent DM, there is
generally a reduction in complications, disease progression,
and incidence of DM. However, not all studies report a
reduction of risk factors associated with DM complications.
Nonetheless, endurance exercise remains intimated with
decreased CVD mortality and a reduction in all-cause
mortality in DM, while keeping the source of its potency
clandestine. Other exercise modalities employed in DM
intervention studies may help uncover the consistency of
exercise to alter associated risk factors, disease incidence,
and progression.
Resistance exercise
For DM1 and DM2, physical activity and exercise training
are beneficial in the facilitation of glucose from within the
blood into muscles without the mediation of insulin, thus
helping to alleviate the need for exogenous insulin or oral
hypoglycemic agents [8]. Resistance training (RT) studies
in diabetics started as an alternative modality of training to
the precedent aerobic exercise program and were later used
in combination with aerobic exercise to seek an optimal
training strategy. RT in the older adult is an important
training modality useful for combating age-associated,
functional declines in muscle strength and endurance
(associated with decreased muscle mass and resting
metabolic activity) [37, 38], increased insulin resistance
[84], decreased flexibility and range of motion [14], and
decreased maximal aerobic capacity [42, 50, 51, 109, 110].
Randomized RT and combined aerobic and resistance
training (CT) studies with DM2 over the last decade have
examined measures of diabetes management (glycated
hemoglobin [6, 7, 16, 18, 21, 29–31, 42, 48, 53, 54, 73,
98], FPG [6, 7, 16, 18, 21, 29–31, 42, 47, 53, 73, 98],
plasma insulin, and insulin sensitivity [6, 27, 30, 31, 47, 54,
98]), anthropometrical markers of diabetic risk (BMI or
weight) [6, 13, 16, 18, 21, 29–31, 42, 48, 53, 54, 72, 98],
the response of cellular proteins involved in glucose
regulation [27, 47], and indicators of cardiovascular risk
(LDL, HDL, triglycerides, and blood pressure [6, 7, 16, 18,
21, 30, 47, 48, 73]).
RT in the elderly
Of the 13 RT studies reviewed, eight were conducted in
older adults with average age between 60 and 80 years [13,
16, 27, 30, 31, 47, 48, 53]. Similarly, among the four CT
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studies, two used older adults with DM2 as their sample
population [7, 21]. The most commonly measured out-
comes were strength (11 out of 13 studies), glycated
hemoglobin (11 out of 13), weight (11 out of 13), fasting
glucose (8 out of 13), and plasma insulin (7 out of 13). It is
interesting to note that despite all of the RT studies
demonstrating significant increases in muscular strength,
there was a low incidence of significant findings for
traditional risk factors for DM-related risk factors. For
instance, only four studies found significant decreases in
A1C after RT [16, 18, 30, 48]; one study found a significant
decrease in weight [30]; three studies found decreased
fasting glucose [6, 18, 53]; and only one study found
significant changes in plasma insulin levels [6]. Moreover,
there were no changes in BMI [6, 29, 31, 42, 53] or aerobic
capacity in the studies measuring these parameters [18, 42,
54]. It is of clinical concern that A1C was not significantly
decreased in the majority of RT studies. It should be noted
that those studies with significant differences in glycated
hemoglobin were at least 16 weeks in duration. Within the
four CT studies in diabetics considered here [7, 21, 73, 98],
three found significant decreases in A1C and fasting
glucose [7, 73, 98]. Proportionately, the CT studies were
more effective at managing glucose and significantly
decreasing A1C.
CVD risk and RT
As mentioned previously, decreasing the risk of cardiovas-
cular events with exercise is an important part of diabetes
management. Unfortunately, the markers of cardiovascular
risk are not uniformly improved within the reviewed RT
studies. Two of the five studies reported significant
decreases of LDL and triglycerides posttraining [18, 48],
while one of the five studies found an increase in HDL
[18]. Similarly, only two studies found significant decreases
in blood pressure after RT [16, 18]. Of the CT studies
reviewed, three measured cholesterol and triglycerides,
while only one found significant improvement in these
measures [7]. This would lead to question whether the
training stimulus for the majority of these RT and CT
studies was sufficient to elicit beneficial adaptations to the
lipid profile and triglycerides, or whether dietary control
was inadequate among subjects.
However, there is evidence that a combined endurance
and RT program may be an adequate stimulus to affect
CVD-related and other DM complication-related risk
factors. Balducci et al. [7] were successful at significantly
improving both diabetic management and cardiovascular
markers. Their yearlong study, using a CT protocol with 62
subjects, found the greatest significant decreases in all
examined parameters (p<0.0001) of managing glucose and
cardiovascular risk factors. The participants exercised
aerobically for 30 min at 40–80% of heart rate reserve
and performed three sets of 12 repetitions of resistance
exercises using free weights and machines at 40 to 60% of
the one-repetition maximum (1-RM). Cauza et al. [18] and
Honkola et al. [48] were similarly successful in improving
glucose control and cardiovascular parameters.
In summary, the effects conferred upon DM progression
by endurance and resistance exercise are numerous, and
myriad benefits are consistently reported. There are no
enough consistent reports that indicate that the positive
effects of exercise on DM are directed at any one or more
associated risk factors. Nonetheless, there are no apparent
reports demonstrating that a well-designed randomized
control trial resulted in no reduction of incidence or micro-
and macrovascular complications due to DM. Ergo, it is
important to emphasize that exercise generally improves
health and increases longevity within the diabetic popula-
tion, and the lack of an unequivocally demonstrable
mechanism does not diminish its inherent potency.
Exercise recommendations
Exercise potency is supported by professional organiza-
tions, such as the American College of Sports Medicine
(ACSM) and the ADA. The ACSM’s Position Stand on
endurance exercise and DM2 [2] currently recommends that
exercise should approximate the volume and intensity
recommended for healthy individuals after appropriately
progressing from existing levels [61]; that is, progression to
moderate intensity aerobic activity leading to the expendi-
ture of approximately 1,000 kcal/week. Similarly, the
ADA’s Position Statement [33] indicates that previous
reports showed positive effects on DM with exercise
intensities between 50 and 80% VO2max, three to four
times a week for 30–60 min/session. Moreover, the ADA
recommends exercise as a valid DM intervention in the
elderly to improve fitness and insulin resistance via
endurance training, and for increasing strength and muscle
mass via RT.
In support, the ACSM recommends RT as part of a
diabetes management strategy to help decrease the risk of
associated complications [2]. The ACSM outlines a
minimum frequency of twice a week; one set of 10 to 15
repetitions of 8 to 10 exercises incorporating larger muscle
groups. The training protocols used within these studies
have varied in the number of resistance exercises (3 to 10),
repetitions (8 to 20), sets (2 to 6), frequency per week (2 to
5), and intensity (40 to 80% 1-RM). The RT studies
showing significantly decreased A1C [16, 18, 30, 48] have
used 2 to 3 bouts per week, 2 to 3 sets of 8 to 15 repetitions
in 5 to 10 whole body exercises up to 85% of 1-RM
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intensity or 10 to 15 repetition maximums for each
exercise. The ACSM statement notes that greater intensity
and volume of exercise may be of greater benefit for
the individual. Based on the reviewed RT studies and the
ACSM guidelines for intensity, this may indicate that the
maximal intensity achievable, considering adherence to
exercise and safety, would provide the greatest training
benefit in managing diabetes.
Considerations
Individuals with DM demonstrate a repertoire of complica-
tions and conditions necessitating careful consideration
before prescribing an exercise intervention. Blood glucose
should be carefully monitored to avoid hypoglycemia
during and after exercise. Neuropathies may prevent the
detection of lacerations or pressure injuries, which may lead
to infection. Hence, properly fitted footwear is imperative.
Older DM patients demonstrate diminished postural control
[65], which may precipitate balance-related falls. Auto-
nomic disruption may lead to orthostatic hypotension [75],
requiring care when moving from prone to supine positions
during exercise. Advanced diabetic retinopathy may be
exacerbated by high-intensity exercise employing the
Valsalva maneuver [1]. In addition, because individuals
with DM are more likely to suffer from CVD, a stress test
should be performed before prescribing any exercise
regimen, whether endurance or resistance. Because both
endurance and resistance training are indicated and favor-
able in the progress and treatment of DM [102], their
incorporation into a regular routine seems efficacious.
Conclusion
The ease with which pernicious diabetic complications
manifest alerts the public and scientific communities to the
attitudinal and physiological inherency of DM. Statistics
reported by the UN [100] project that the world’s
population will increase from 6.5 billion today to 9.1
billion in 2050 with the senior demographic being the
largest growing segment of the population. Thus, as DM
prevalence grows with increasing age, the call to arms
becomes decidedly urgent and bitter. Although some
natural and unalterable propensity toward elevated suscep-
tibility exists with aging, it seems unlikely that all attempts
to improve our health and alter our fates will be met with an
unforgiving and implacable adversary. Clearly, exercise (the
very activity limited by diabetes) reveals that diabetes is a
disease willing to be placated. The role of pancreatic beta
cells in disease progression is becoming defined; the known
biochemical pathways activated by the effects of hypergly-
cemia, hyperlipidemia, and oxidative stress within the DM
patient population are increasingly controllable; and dys-
functions at the level of the insulin receptor and intracel-
lular signaling are becoming progressively delineated. The
ability of exercise to improve health and confer physical
fitness in a DM environment, in spite of a multitude of
injurious sequelae, is evidenced by its reduction of all-cause
mortality, CVD mortality, and incidence and progression of
complications. Still, the volume of evidence required for
our complete understanding of DM and the contribution of
exercise to the attenuation of its complications is legion.
The mechanistic action on DM attributable to exercise
remains opaque and provocatively clandestine, but, by
virtue of evidence, remains steadfastly beneficial.
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